Rituximab Protects against Development of Atherosclerotic Cardiovascular Disease after Kidney Transplantation, a Propensity Matched Analysis
Severance hospital, Seoul, Korea, Republic of
Meeting: 2019 American Transplant Congress
Abstract number: C203
Keywords: B cells, Kidney transplantation, Monoclonal antibodies, Morbidity
Session Information
Session Name: Poster Session C: Kidney: Cardiovascular and Metabolic
Session Type: Poster Session
Date: Monday, June 3, 2019
Session Time: 6:00pm-7:00pm
Presentation Time: 6:00pm-7:00pm
Location: Hall C & D
*Purpose: Recent studies have implicated B cells in atherosclerosis and have verified the atheroprotective effect of rituximab. We sought to explore the effects of rituximab induction on atherosclerotic cardiovascular disease (ASCVD) in the aftermath of KT
*Methods: Using a single-center KT database, we performed propensity-matched analysis to investigate the association between rituximab and posttransplant ASCVD.
*Results: Among 1299 eligible patients, 239 given rituximab induction were matched with 401 controls in a 1:2 propensity score matching process. The cumulative rate of ASCVD during 8 years of follow-upwas significantly lower in rituximab-treated patients, compared with matched controls (3.7% vs. 11.2%; P=0.012). However, all-cause mortality did not differ by group (2.9% vs. 4%; P=0.943). In multivariable Cox analysis, rituximab proved independently protective of ASCVD (hazard ratio [HR]=0.34, 95% confidence interval [CI]: 0.14-0.83). The lower risk of ASCVD seen with rituximab induction reached significance only in patient subsets of diabetes mellitus, pretransplant dialysis, or older age (>50 years).
*Conclusions: Rituximab induction confers a lower risk of ASCVD during the posttransplant period. This atheroprotective effect appears particularly beneficial in patients whose risk of ASCVD is heightened.
$$MISSING OR BAD TABLE SPECIFICATION {52AF88CC-24C4-4027-A0BA-BF56CED9B2CE}$$
To cite this abstract in AMA style:
Kim D, Lee J, Lee J, Kim B, Kim M, Il SSoon, Kim Y, Huh K, Kim S, Joo D, In K, Kim E. Rituximab Protects against Development of Atherosclerotic Cardiovascular Disease after Kidney Transplantation, a Propensity Matched Analysis [abstract]. Am J Transplant. 2019; 19 (suppl 3). https://atcmeetingabstracts.com/abstract/rituximab-protects-against-development-of-atherosclerotic-cardiovascular-disease-after-kidney-transplantation-a-propensity-matched-analysis/. Accessed November 22, 2024.« Back to 2019 American Transplant Congress